welcome to the Imu thread .
HerVax is not our only asset . you could well include the same valuation assumptions for the PD1Vaxx and same again for CF33.
But why assume only 50% market share if we can demonstrate far greater safety and longer life expectations than the existing mono clonal antibodies? Those existing blockbuster drugs could well be made redundant and unethical if the data we’ve seen already for HerVaxx is shown across the pipeline.
And it would be fair to say Big Pharma might even pay a greater multiple for an entire platform of “next gen” vaccines than a stand alone product using outdated technology.
welcome to the Imu thread .HerVax is not our only asset . you...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
